The global artificial insemination market size is expected to reach USD 2.9 billion by 2026 registering a CAGR of 8.4%, according to a new report by Grand View Research, Inc. Over the past few years, infertility has become a major public health concern across the globe. Artificial insemination is usually the preferred first-line treatment to tackle infertility. Lifestyle changes, delay in pregnancy, and hormonal issues are some of the reasons contributing to the rise in fertility-related problems. According to the United Nations, the global fertility rate is expected to decline to 2.2% by 2050. In developing or underdeveloped nations, medical consultation regarding infertility was not easily accessible.
Hence, there was a lack of awareness about available assisted reproductive techniques including artificial or donor insemination and IVF. The average cost of performing an IUI is around USD 865. The success rate for each cycle is around 4 to 5%, which can be increased to about 7 to 16% by consuming fertility drugs. However, older women are not encouraged to go through IUI due to slim chances of success and further complications. Several fertility problems can be addressed through IUI, such as semen allergy, unexplained infertility, and Sexually Transmitted Diseases (STDs).
https://www.grandviewresearch.com/industry-analysis/artificial-insemination-market
Further key findings from the study suggest:
- Artificial insemination is a first-line of infertility treatment, as it is minimally invasive and less expensive as compared to IVF
- In some countries, such as U.S. and U.K., same-sex couples are provided insurance coverage for artificial insemination procedures
- Intrauterine insemination held majority of the market share in 2018 and is likely to be the fastest-growing segment over the forecast period as it is the most common and non-invasive procedure
- Fertility clinics held a majority of the market share in the year 2018 due to higher number of medical facilities offering infertility treatments
- Europe held a majority of the market share in the year 2018. North America was the second-largest market in 2018
- Some of the key companies in the global artificial insemination market include Vitrolife; Genea Ltd.; Rinovum Women’s Health, LLC; Pride Angel; Hi-Tech Solutions; FUJIFILM Irvine Scientific; Kitazato Corp.; and Rocket Medical plc
Grand View Research has segmented the global artificial insemination market on the basis of type, end use, source type, and region:
Artificial Insemination Type Outlook (Revenue, USD Million, 2015 - 2026)
- Intrauterine
- Intracervical
- Intravaginal
- Intratubal
Artificial Insemination End Use Outlook (Revenue, USD Million, 2015 - 2026)
- Fertility Clinics & Other Facilities
- Home
Artificial Insemination Source Type Outlook (Revenue, USD Million, 2015 - 2026)
- AIH-Husband
- AID-Donor
Artificial Insemination Regional Outlook (Revenue, USD Million, 2015 - 2026)
- North America
- US.
- Canada
- Europe
- UK.
- Germany
- Asia Pacific
- Japan
- China
- India
- Latin America
- Brazil
- Mexico
- Middle East & Africa
- South Africa
About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.
No comments:
Post a Comment